EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Endobronchial ultrasound-guided transbronchial needle aspiration validated with video-assisted mediastinoscopic lymphadenectomy in the mediastinal restaging of patients with stage IIIA non-small cell lung cancer after induction therapy

Bruno García-Cabo, Nina Reig, Ramón Rami-Porta, Sergi Call, Lluís Esteban, Bienvenido Barreiro, Efraín Reyes, Carme Obiols, Juan Manuel Ochoa, Xavier Morlius, Xavier Tarroch, Mireia Serra und 1 weitere

Therapeutic Advances in Respiratory Disease · 2024-01 · 18

DOI: 10.1177/17534666241301284 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Respiratory Disease, online erschienen am 27.11.2024. Verfasst von Bruno García-Cabo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonology Department, Hospital Universitari Mútua Terrassa, University of Barcelona, Terrassa, Barcelona, Spain. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Staging, Lymph Node Excision. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The role of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) validated with video-assisted mediastinoscopic lymphadenectomy (VAMLA) for mediastinal restaging of patients with non-small cell lung cancer (NSCLC) after induction therapy has never been described.

Objective

To report on our experience in this clinical setting.

Design

Retrospective analysis of a prospectively built database.

Methods

Patients with stage IIIA (N2) NSCLC who underwent EBUS-TBNA for mediastinal restaging after induction therapy were included. The sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV), and diagnostic accuracy of EBUS-TBNA and VAMLA for mediastinal restaging were calculated. The number of patients needed to undergo confirmatory VAMLA (NNT) after a negative EBUS-TBNA for mediastinal restaging to avoid a case of pathologic (p) N2 disease after resection was also calculated.

Results

Forty-six patients underwent EBUS-TBNA which was positive in 12 patients and negative in 34. Patients with a negative EBUS-TBNA underwent VAMLA which was positive in seven cases. Of the other 27 patients with a negative VAMLA, 26 underwent resection that did not show N2 disease. The sensitivity, specificity, NPV, PPV, and diagnostic accuracy of EBUS-TBNA for restaging were 63.1%, 100%, 79.4%, 100%, and 84.7%, respectively. The sensitivity, specificity, NPV, PPV, and diagnostic accuracy of confirmatory VAMLA after EBUS-TBNA was 100%. The NNT confirmatory VAMLA after a negative EBUS-TBNA to avoid a case of pN2 disease at resection was five patients.

Conclusion

EBUS-TBNA must remain as the first-choice test for invasive mediastinal restaging. However, the results of our study in terms of sensitivity and NPV, even considering the small size of our population, suggest that negative results of EBUS-TBNA should be interpreted with caution and surgical exploration of the mediastinum (specially VAMLA, if available) should be considered in these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsNeoplasm StagingLymph Node ExcisionMediastinoscopyEndoscopic Ultrasound-Guided Fine Needle AspirationPredictive Value of TestsHumansMaleFemaleRetrospective StudiesMiddle AgedAgedLymphatic MetastasisDatabases, FactualLymph NodesMediastinumInduction Chemotherapy

Stichwörter der Autor:innen

EBUS-TBNAN2VAMLAlung cancerlung cancer restagingrestaging

Autor:innen und Institutionen

  • Pulmonology Department, Hospital Universitari Mútua Terrassa, University of Barcelona, Terrassa, Barcelona, Spain.
  • Department of Medicine, School of Medicine and Health Sciences, University of Barcelona, Terrassa, Barcelona, Spain.
  • Thoracic Surgery Department, Hospital Universitari Mútua Terrassa, University of Barcelona, Terrassa, Barcelona, Spain.
  • Network of Centers for Biomedical Research on Respiratory Diseases (CIBERES), Lung Cancer Group, Terrassa, Barcelona, Spain.
  • Department of Morphological Sciences, Medical School, Autonomous University of Barcelona, Bellaterra, Barcelona, Spain.
  • Pathology Department, Hospital Universitari Mútua Terrassa, University of Barcelona, Terrassa, Barcelona, Spain.

ORCID-Profile: José Sanz-Santos

Zitieren

APA

García-Cabo, B., Reig, N., Rami-Porta, R., Call, S., Esteban, L., Barreiro, B., Reyes, E., Obiols, C., Ochoa, J. M., Morlius, X., Tarroch, X., Serra, M., & Sanz-Santos, J. (2024). Endobronchial ultrasound-guided transbronchial needle aspiration validated with video-assisted mediastinoscopic lymphadenectomy in the mediastinal restaging of patients with stage IIIA non-small cell lung cancer after induction therapy. Therapeutic Advances in Respiratory Disease, 18. https://doi.org/10.1177/17534666241301284

Vancouver

García-Cabo B, Reig N, Rami-Porta R, Call S, Esteban L, Barreiro B, et al. Endobronchial ultrasound-guided transbronchial needle aspiration validated with video-assisted mediastinoscopic lymphadenectomy in the mediastinal restaging of patients with stage IIIA non-small cell lung cancer after induction therapy. Therapeutic Advances in Respiratory Disease. 2024;18. doi:10.1177/17534666241301284

BibTeX
@article{GarcaCabo2024,
  author = {García-Cabo, Bruno and Reig, Nina and Rami-Porta, Ramón and Call, Sergi and Esteban, Lluís and Barreiro, Bienvenido and Reyes, Efraín and Obiols, Carme and Ochoa, Juan Manuel and Morlius, Xavier and Tarroch, Xavier and Serra, Mireia and Sanz-Santos, José},
  title = {Endobronchial ultrasound-guided transbronchial needle aspiration validated with video-assisted mediastinoscopic lymphadenectomy in the mediastinal restaging of patients with stage IIIA non-small cell lung cancer after induction therapy},
  journal = {Therapeutic Advances in Respiratory Disease},
  year = {2024},
  volume = {18},
  doi = {10.1177/17534666241301284}
}
Kostenlos starten →